Latest Biogen News & Updates
See the latest news and media coverage for Biogen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company for neurological, immune, and rare diseases
biogen.com- Headquarters
- Cambridge, United States
- Company type
- Public company
- Number of employees
- 7,500–10,000
Last updated
Latest news about Biogen
In short: Biogen outperformed first-quarter profit expectations, expanded its immunology pipeline via acquisitions, and received FDA approval for Spinraza.
Company announcements
-
Biogen completed acquisition of Apellis Pharmaceuticals
The deal adds EMPAVELI and SYFOVRE, bolstering nephrology pipeline and expected to be accretive to EPS by 2027.
-
Biogen reports diranersen shows tau reduction and cognitive benefit
The CELIA study missed primary endpoint but robust biomarker and cognitive data support advancement to registrational development.
-
Biogen announces FDA extends LEQEMBI IQLIK review
FDA extends sBLA review by three months to August 24, 2026, for subcutaneous starting dose in early Alzheimer’s. No approvability concerns raised.
-
Biogen doses first patient in Phase 3 SMA study
This milestone advances potential new treatments for SMA patients and families. Ongoing research targets unmet needs.
Media coverage
-
Biogen Completes Acquisition of Apellis Pharmaceuticals
Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for...
-
Biogen Shares Rise on 'Compelling' Results From Recent Trial for Alzheimer's Disease Treatment
Biogen before the bell said its treatment, diranersen, demonstrated slowing of clinical decline in early Alzheimer's disease across all studied doses in a recent trial...
-
NICE Recommends Biogen's Spinraza, Roche's Evrysdi for SMA Patients in England
The latest decision makes these treatments routinely available after having been accessible only through a managed access scheme.
-
Stocks making the biggest moves premarket: Versant, Biogen, Bullish, Cisco and more
These are the stocks posting the largest moves in the premarket.
Track Biogen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Biogen competitors & trending companies
Browse news for competitors to Biogen and other trending companies.
Ipsen
Sobi
Mirum Pharmaceuticals
UCB
Dynatrace
Wolfspeed
Recursive
Global Partners
SELLAS
System1
Eventbrite
BuzzFeed
Ecopetrol
QCi
MARA
Microvast
Navitas
Plug
Alpha Tau
WhiteFiber
Circle
TAT
Jet.AI
Road Rental
Lucky Strike
Cheniere
Photronics
Sphere 3D
AMC
Carriage Services
Canaan
O-I
TMC
Agora
Applied Digital